Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

The MDASEâ"¢ patents are not included in Halozyme's ENHANZE licensing program and are distinct from its ENHANZE patents. Therefore, the outcome of the infringement lawsuit against Merck will not impact ENHANZE, the ability of any licensee to use ENHANZE, or revenues Halozyme receives from ENHANZE licensees. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug ...